Safety margin of embolized area can reduce local recurrence of hepatocellular carcinoma after superselective transarterial chemoembolization
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: We aimed to determine the relationship between the safety margin of an embolized area and local tumor recurrence (LTR) of patients with hepatocellular carcinoma (HCC) who underwent superselective transarterial chemoembolization (TACE). Methods: The medical records of 77 HCC patients with 109 HCC nodules who underwent superselective TACE were retrospectively analyzed for LTR. Univariate and multivariate analyses were performed for 16 potential factors using Cox proportional hazard regression. Iodized oil deposition on cone-beam computed tomography (CBCT) imaging was divided into three grades: A=complete tumor staining and complete circumferential safety margin, B=complete tumor staining but incomplete safety margin, C=incomplete tumor staining. The effect of a safety margin on LTR was evaluated by comparison between grade A and B group. Results: Univariate and multivariate analyses revealed that grade A iodized oil deposition and portal vein visualization were the only two independent significant factors of LTR (P<0.001 and P=0.029, respectively). The 12- and 24-month LTR rates of tumors for grade A (n=62), grade B (n=30), and grade C (n=17) were 16% vs. 41% vs. 100% and 16% vs. 61% vs. 100%, respectively (P<0.001). The tumors in the grade A group had a 75% risk reduction in LTR (odds ratio, 0.25; 95% confidence interval, 0.10 to 0.64; P=0.004) compared to the grade B group. Conclusions: LTR was significantly lower when a greater degree of iodized oil deposition occurred with a complete circumferential safety margin. In superselective TACE, the safety margin of the embolized areas using intraprocedural CBCT affected LTR in HCC patients.
Abstract
Background/Aims: We aimed to determine the relationship between the safety margin of an embolized area and local tumor recurrence (LTR) of patients with hepatocellular carcinoma (HCC) who underwent superselective transarterial chemoembolization (TACE). Methods: The medical records of 77 HCC patients with 109 HCC nodules who underwent superselective TACE were retrospectively analyzed for LTR. Univariate and multivariate analyses were performed for 16 potential factors using Cox proportional hazard regression. Iodized oil deposition on cone-beam computed tomography (CBCT) imaging was divided into three grades: A=complete tumor staining and complete circumferential safety margin, B=complete tumor staining but incomplete safety margin, C=incomplete tumor staining. The effect of a safety margin on LTR was evaluated by comparison between grade A and B group. Results: Univariate and multivariate analyses revealed that grade A iodized oil deposition and portal vein visualization were the only two independent significant factors of LTR (P<0.001 and P=0.029, respectively). The 12- and 24-month LTR rates of tumors for grade A (n=62), grade B (n=30), and grade C (n=17) were 16% vs. 41% vs. 100% and 16% vs. 61% vs. 100%, respectively (P<0.001). The tumors in the grade A group had a 75% risk reduction in LTR (odds ratio, 0.25; 95% confidence interval, 0.10 to 0.64; P=0.004) compared to the grade B group. Conclusions: LTR was significantly lower when a greater degree of iodized oil deposition occurred with a complete circumferential safety margin. In superselective TACE, the safety margin of the embolized areas using intraprocedural CBCT affected LTR in HCC patients.
참고문헌 (22)
- Torre LA, "Global cancer statistics, 2012", CA Cancer J Clin, 65, pp.87~108 (2015)
- Colella G, "Hepatocellular carcinoma: comparison between liver transplantation, resective surgery, ethanol injection, and chemoembolization", Transpl Int, 11(Suppl 1), pp.S193~S196 (1998)
- Segawa T, "Evaluation of hepatectomy in small hepatocellular carcinoma--comparison with transcatheter arterial embolization therapy", Nihon Geka Gakkai Zasshi, 93, pp.1095~1099 (1992)
- Lo CM, "Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma", Hepatology, 35, pp.1164~1171 (2002)
- Llovet JM, "Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma : a randomised controlled trial", Lancet, 359, pp.1734~1739 (2002)
- Matsui O, "Small hepatocellular carcinoma : treatment with subsegmental transcatheter arterial embolization", Radiology, 188, pp.79~83 (1993)
- Miyayama S, "Ultraselective transcatheter arterial chemoembolization with a 2-f tip microcatheter for small hepatocellular carcinomas : relationship between local tumor recurrence and visualization of the portal vein with iodized oil", J Vasc Interv Radiol, 18, pp.365~376 (2007)
- Iwamoto S, "Excellent outcomes with angiographic subsegmentectomy in the treatment of typical hepatocellular carcinoma : a retrospective study of local recurrence and long-term survival rates in 120 patients with hepatocellular carcinoma", Cancer, 116, pp.393~399 (2010)
- Bronowicki JP, "Transcatheter oily chemoembolization for hepatocellular carcinoma. A 4-year study of 127 French patients", Cancer, 74, pp.16~24 (1994)
- Kim KW, "Safety margin assessment after radiofrequency ablation of the liver using registration of preprocedure and postprocedure CT images", AJR Am J Roentgenol, 196, pp.W565~W572 (2011)
- Sasaki A, "Microsatellite distribution and indication for locoregional therapy in small hepatocellular carcinoma", Cancer, 103, pp.299~306 (2005)
- Pung L, "The role of cone-beam CT in transcatheter arterial chemoembolization for hepatocellular carcinoma : a systematic review and metaanalysis", J Vasc Interv Radiol, 28, pp.334~341 (2017)
- Deschamps F, "Computed analysis of three-dimensional cone-beam computed tomography angiography for determination of tumor-feeding vessels during chemoembolization of liver tumor : a pilot study", Cardiovasc Intervent Radiol, 33, pp.1235~1242 (2010)
- Miyayama S, "Identification of small hepatocellular carcinoma and tumor-feeding branches with cone-beam CT guidance technology during transcatheter arterial chemoembolization", J Vasc Interv Radiol, 24, pp.501~508 (2013)
- Iwazawa J, "Clinical utility and limitations of tumor-feeder detection software for liver cancer embolization", Eur J Radiol, 82, pp.1665~1671 (2013)
- Bruix J, "Management of hepatocellular carcinoma : an update", Hepatology, 53, pp.1020~1022 (2011)
- Brown DB, "Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy", J Vasc Interv Radiol, 20(7 Suppl), pp.S219~S226 (2009)
- Yamada R, "Hepatic artery embolization in 120 patients with unresectable hepatoma", Radiology, 148, pp.397~401 (1983)
- Uchida H, "Transcatheter hepatic segmental arterial embolization using lipiodol mixed with an anticancer drug and gelfoam particles for hepatocellular carcinoma", Cardiovasc Intervent Radiol, 13, pp.140~145 (1990)
- Bannangkoon K, "Rate and predictive factors for sustained complete response after selective transarterial chemoembolization(TACE)in patients with hepatocellular carcinoma", Asian Pac J Cancer Prev, 19, pp.3545~3550 (2018)
- Miyayama S, "Comparison of local control in transcatheter arterial chemoembolization of hepatocellular carcinoma ≤6 cm with or without intraprocedural monitoring of the embolized area using cone-beam computed tomography", Cardiovasc Intervent Radiol, 37, pp.388~395 (2014)
- Goseki N, "Nourishment of hepatocellular carcinoma cells through the portal blood flow with and without transcatheter arterial embolization", Cancer, 76, pp.736~742 (1995)